pdufa.bio
CalendarDecisionsReadoutsPatents
Drug IndexStocksScreenerConferencesAdvisory Committees
StudiesRun-up by YearLearnGlossaryMethodologyAPIAccount
Pro
Home › FDA Decisions › PHRRF 2025-08-11

PHRRF FDA Decision Approved · 2025-08-11

Updated ·next FDA decision on the calendar

Price into the decision (T-120)

PDUFA 8/11/25$0.413$0.122/24/25
Daily close, T-120 (2/24/25) through T+5. Run-up high $0.413 on 8/5/25, low $0.12 on 4/14/25 (T-120 to T-1). FDA decision 8/11/25. Historical price action, not a forecast.

Decision facts

FDA decision date2025-08-11
DrugKETARX (ketamine)
IndicationSurgical pain management
Outcome✓ Approvedprimary-sourced
Decision-day move+8.3%
T-120 run-up (low→high)+242.0% ($0.12→$0.41)
ValidationVerified 2026-08-12: Drugs@FDA, application ANDA217858, action date 2025-08-07
Market-cap tierNano
Cohort decision-day move (history)8.0% median (n=117)

Cohort move is the historical median absolute decision-day move for this market-cap tier across our run-up study. History, not a prediction.

See the full 2026 PDUFA calendar →

Questions

Was KETARX (ketamine) approved by the FDA?

Yes. The FDA approved the application for KETARX (ketamine) on August 11, 2025. The primary source is linked on this page.

What was KETARX (ketamine) under FDA review for?

The application covered Surgical pain management. The FDA approved the application on August 11, 2025.

How did PHRRF stock react to the FDA decision?

On the decision day PHRRF moved +8.3%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.